FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362543841> ?p ?o ?g. }

• W4362543841 endingPage "886" @default.
• W4362543841 startingPage "886" @default.
• W4362543841 abstract "Abstract Chimeric Antigen Receptor (CAR) T cell therapy is a new type of “living drug” that has proven to be a powerful immunotherapy for hematologic malignancies. To date, there are six CAR-T products approved by the FDA for hematologic malignancies, four targeting CD19, and two targeting B-cell maturation antigen (BCMA). However, this success has not yet been transferred to solid tumors. A major hurdle is the on-target off-tumor toxicities due to the shared expression of target antigen on normal tissues. Carbonic anhydrase IX (CAIX) is highly expressed in clear cell renal cell carcinoma (ccRCC); however, it is also expressed on bile duct at a lower physiological level leading to off-tumor toxicity of CAIX targeted therapies. The first anti-CAIX CAR-T studies, using the 1st generation G250 CAR-T cells plus IL-2 to treat patients with metastatic ccRCC, caused severe liver enzyme abnormalities in the treated patients after CAR-T cell infusions. To understand CAIX expression on tumor and normal tissues, we quantified CAIX expression on ccRCC patient samples and healthy bile duct tissues using direct stochastic optical reconstruction microscopy (dSTORM) which provides single-molecule resolution. Tet-On inducible CAIX expressing cell lines were established to mimic various CAIX densities on normal tissue and tumor samples. Using biolayer interferometry (BLI) and avidity analyzer, we identified a low-affinity, high-avidity anti-CAIX CAR G9. G9 CAR-T cells only kill CAIX high ccRCC tumor cells but not CAIX low normal cholangiocytes, and exhibited a CAIX density dependent response to Tet-On inducible CAIX expressing cell lines. Compared to high-affinity G250 CAR-T cells, G9 showed a better safety profile and a wider therapeutic window. G9 demonstrated a superior ex vivo efficacy on ccRCC patient derived organotypic tumor spheroids (PDOTS) 3D cultures which recapitulate ccRCC patient tumor microenvironment (TME), as well as low toxicity on cholangiocyte derived organotypic spheroids (CDOS). In summary, affinity/avidity fine-tuned CAIX targeted CAR-T cell therapy holds promise to achieve cures of ccRCC by efficaciously killing tumor cells and mitigating on-target off-tumor toxicity on normal tissues. Citation Format: Yufei Wang, Alicia Buck, Gabriella Kastrunes, Rabia Abbas, Michael Lynch, Zhou Zhong, Song-My Hoang, Andras Miklosi, Kun Huang, Jae-Won Cho, Marion Grimaud, Cecile Razimbaud, Matthew Chang, Atef Fayed, Audrey Apollon, Nithyassree Murugan, Ze-Hua Li, Tran Thai, Luann Zerefa, Brandon Piel, Elena Ivanova, Amy Cameron, Quang-De Nguyen, Zhu Zhu, Kevin Wei, Yasmin Nabil Laimon, Aseman Bagheri Sheshdeh, Sabina Signoretti, David A. Braun, Catherine J. Wu, Toni K. Choueiri, Jon Wee, Cloud P. Paweletz, Martin Hemberg, Aedin C. Culhane, David A. Barbie, Gordon J. Freeman, Wayne A. Marasco. Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 886." @default.
• W4362543841 created "2023-04-06" @default.
• W4362543841 creator A5000780125 @default.
• W4362543841 creator A5003823914 @default.
• W4362543841 creator A5015008638 @default.
• W4362543841 creator A5021269788 @default.
• W4362543841 creator A5022843288 @default.
• W4362543841 creator A5031091137 @default.
• W4362543841 creator A5034868438 @default.
• W4362543841 creator A5035182164 @default.
• W4362543841 creator A5035644250 @default.
• W4362543841 creator A5041611438 @default.
• W4362543841 creator A5046442233 @default.
• W4362543841 creator A5046795494 @default.
• W4362543841 creator A5047701430 @default.
• W4362543841 creator A5048975003 @default.
• W4362543841 creator A5049557991 @default.
• W4362543841 creator A5049910071 @default.
• W4362543841 creator A5052504518 @default.
• W4362543841 creator A5053297258 @default.
• W4362543841 creator A5056573353 @default.
• W4362543841 creator A5058643322 @default.
• W4362543841 creator A5060353514 @default.
• W4362543841 creator A5064640663 @default.
• W4362543841 creator A5066563061 @default.
• W4362543841 creator A5068928052 @default.
• W4362543841 creator A5069300441 @default.
• W4362543841 creator A5071825149 @default.
• W4362543841 creator A5072438750 @default.
• W4362543841 creator A5075310347 @default.
• W4362543841 creator A5075386432 @default.
• W4362543841 creator A5076637826 @default.
• W4362543841 creator A5077525581 @default.
• W4362543841 creator A5078482949 @default.
• W4362543841 creator A5080840619 @default.
• W4362543841 creator A5082180580 @default.
• W4362543841 creator A5084013842 @default.
• W4362543841 creator A5086151912 @default.
• W4362543841 creator A5088161188 @default.
• W4362543841 creator A5089546439 @default.
• W4362543841 date "2023-04-04" @default.
• W4362543841 modified "2023-09-27" @default.
• W4362543841 title "Abstract 886: Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects" @default.
• W4362543841 doi "https://doi.org/10.1158/1538-7445.am2023-886" @default.
• W4362543841 hasPublicationYear "2023" @default.
• W4362543841 type Work @default.
• W4362543841 citedByCount "0" @default.
• W4362543841 crossrefType "journal-article" @default.
• W4362543841 hasAuthorship W4362543841A5000780125 @default.
• W4362543841 hasAuthorship W4362543841A5003823914 @default.
• W4362543841 hasAuthorship W4362543841A5015008638 @default.
• W4362543841 hasAuthorship W4362543841A5021269788 @default.
• W4362543841 hasAuthorship W4362543841A5022843288 @default.
• W4362543841 hasAuthorship W4362543841A5031091137 @default.
• W4362543841 hasAuthorship W4362543841A5034868438 @default.
• W4362543841 hasAuthorship W4362543841A5035182164 @default.
• W4362543841 hasAuthorship W4362543841A5035644250 @default.
• W4362543841 hasAuthorship W4362543841A5041611438 @default.
• W4362543841 hasAuthorship W4362543841A5046442233 @default.
• W4362543841 hasAuthorship W4362543841A5046795494 @default.
• W4362543841 hasAuthorship W4362543841A5047701430 @default.
• W4362543841 hasAuthorship W4362543841A5048975003 @default.
• W4362543841 hasAuthorship W4362543841A5049557991 @default.
• W4362543841 hasAuthorship W4362543841A5049910071 @default.
• W4362543841 hasAuthorship W4362543841A5052504518 @default.
• W4362543841 hasAuthorship W4362543841A5053297258 @default.
• W4362543841 hasAuthorship W4362543841A5056573353 @default.
• W4362543841 hasAuthorship W4362543841A5058643322 @default.
• W4362543841 hasAuthorship W4362543841A5060353514 @default.
• W4362543841 hasAuthorship W4362543841A5064640663 @default.
• W4362543841 hasAuthorship W4362543841A5066563061 @default.
• W4362543841 hasAuthorship W4362543841A5068928052 @default.
• W4362543841 hasAuthorship W4362543841A5069300441 @default.
• W4362543841 hasAuthorship W4362543841A5071825149 @default.
• W4362543841 hasAuthorship W4362543841A5072438750 @default.
• W4362543841 hasAuthorship W4362543841A5075310347 @default.
• W4362543841 hasAuthorship W4362543841A5075386432 @default.
• W4362543841 hasAuthorship W4362543841A5076637826 @default.
• W4362543841 hasAuthorship W4362543841A5077525581 @default.
• W4362543841 hasAuthorship W4362543841A5078482949 @default.
• W4362543841 hasAuthorship W4362543841A5080840619 @default.
• W4362543841 hasAuthorship W4362543841A5082180580 @default.
• W4362543841 hasAuthorship W4362543841A5084013842 @default.
• W4362543841 hasAuthorship W4362543841A5086151912 @default.
• W4362543841 hasAuthorship W4362543841A5088161188 @default.
• W4362543841 hasAuthorship W4362543841A5089546439 @default.
• W4362543841 hasConcept C121608353 @default.
• W4362543841 hasConcept C126322002 @default.
• W4362543841 hasConcept C147483822 @default.
• W4362543841 hasConcept C179223381 @default.
• W4362543841 hasConcept C203014093 @default.
• W4362543841 hasConcept C2777701055 @default.
• W4362543841 hasConcept C2781230642 @default.
• W4362543841 hasConcept C3875195 @default.
• W4362543841 hasConcept C502942594 @default.
• W4362543841 hasConcept C71924100 @default.
• W4362543841 hasConcept C8891405 @default.
• W4362543841 hasConceptScore W4362543841C121608353 @default.

• next